Loading…
Loading…
EXEL does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EXEL and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EXEL and 80,000+ other tickers.
See exactly how EXEL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EXEL and 80,000+ other tickers.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several…
Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,986,035 shares of the biotechnology company's stock after selling 57,995 shares during the
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,707,715 shares of the biotechnology company's stock after acquiring an additional 323,895 shares during the period. Allspring Global
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.